Erin D. Farrell Partner Pro Bono Program Chair


Parle :  Anglais

Téléphone principal : +1 416-369-7337

Fax : +1 416-862-7661

Courriel : erin.farrell@gowlingwlg.com

Télécharger vCard


Bureau principal :  Toronto




Erin D. Farrell

Erin Farrell is a partner in Gowling WLG's Toronto office, practising in the firm's advocacy department. Her practice focuses on a variety of commercial litigation matters, including class actions, product and professional liability, environmental law and municipal liability.

Erin represents professionals in both civil and administrative matters, and has defended a number of Canadian and foreign clients in the pharmaceutical, medical device and manufacturing sectors in litigation. She also has extensive experience in the banking sector, advising clients on a range of litigation matters, including a variety of motions and injunctions.

Erin has appeared before all levels of court in Ontario and has also represented clients before regulatory bodies and tribunals.

Prior to pursuing a career in law, Erin conducted genetics research at a university in Germany, and at a large pharmaceutical company in California. Along with her juris doctor, she holds a bachelor of science (hons.) in biochemistry (nutrition) and a master of science in biotechnology.

Erin is Chair of Gowling WLG's significant Pro Bono program. She also participates in a variety of Pro Bono Ontario programs, providing legal advice and acting as duty counsel for unrepresented litigants before courts and the Ontario Human Rights Tribunal.

Outside of work, Erin is an active member of The Advocates' Society, serving on the 10+ Standing Committee (focused on mid-career advocates) and a variety of task forces. She also regularly volunteers for Ryerson University's LPP Trial Advocacy training program.

Associations professionnelles

  • Canadian Bar Association
  • Ontario Bar Association
  • The Advocates' Society

Erin has co-authored a number of articles on a wide range of topics including class actions, genetics and insurance law. Some of her publications include:

  • "Climate change regulatory update: The "Made-in-Ontario Environment Plan" — More carrots, fewer sticks and a dash of sunlight," Environmental Law newsletter, December 2018
  • "One person's trash is the new government's treasure: The Ontario government stays the course on waste management and the "Made-in-Ontario Environmental Plan," Environmental Law newsletter, December 2018
  • "Supreme Court of Canada makes a clear choice as to who bears the loss on cheque fraud," Financial Institutions & Services newsletter, November 2017
  • "Cybersecurity and medical devices: Electronic medical data increases product liability risk for medical device manufacturers," Tech News newsletter, May 2016
  • "Ontario Court of Appeal gives much-needed clarity to bank's defences in cases of fraud," Commercial Litigation Bulletin, February 2016
  • "Not so fast: Simply issuing a new claim, rather than amending an existing claim to add a new defendant, may be an abuse of process," On-Risk E-Bulletin newsletter, January 2016
  • "Farhat v. Monteanu: Commencement of Limitation Periods in Motor Vehicle Accident Litigation (Updated)," August 2015
  • "No co-operation to streamline trial? No entitlement to costs," July 2015
  • "A tale of two jewellers: Bank successfully appeals conversion judgement," April 2015
  • "Ambiguity is as ambiguity does: Another cautionary tale from a Canadian appellate court on the importance of clear drafting," published in Gowlings' On Risk E-Bulletin newsletter, February 2015
  • "Boyce v Co-Operators General Insurance Co — If You Want Your Limits, Check Your Limitations," published in the Canadian Journal of Insurance Law, January 2014
  • "Preferable Procedure Revisited: Supreme Court of Canada Examines Preferable Procedure for First Time since Hollick," published in the Gowlings Commercial Litigation Bulletin, December 2013
  • "Spotlight on Gene Patents," published in Intellectual Asset Management, October 2013
  • "Bike Accidents and Municipal Liability," published in Canadian Underwriter, October 2011
  • "An Integrative Genomic Analysis Identifies Bhmt2 as a Diet-Dependent Genetic Factor Protecting Against Acetaminophen-Induced Liver Toxicity," published in Genome Research, November, 2009
  • "Pharmacogenomics and Drug Development: The Impact of U.S. FDA Post-approval Tracking on Clinical Pharmacology," Personalized Medicine, March 2008
  • "In Silico and In Vitro Pharmacogenetic Analysis in Mice," Proceedings of the National Academy of Sciences, November 2007
  • "In Silico Pharmacogenetics: Warfarin Metabolism," Nature Biotechnology, May 2006